{"id":818981,"date":"2025-02-27T07:09:10","date_gmt":"2025-02-27T12:09:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"modified":"2025-02-27T07:09:10","modified_gmt":"2025-02-27T12:09:10","slug":"xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","title":{"rendered":"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025<\/b><\/p>\n<p class=\"bwalignc\"><i>Conference call and webcast at 8:30am ET<\/i><\/p>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results.<\/p>\n<p>\nTo pre-register for the call, please go to the following link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FIb0YCQWX2nH6VQyNIOIMSGN2jL%3Fdomain%3Dgoogle.com&amp;esheet=54213235&amp;newsitemid=20250227136020&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.netroadshow.com%2Fevents%2Flogin%3Fshow%3Decd4fc1e%26amp%3BconfId%3D76382&amp;index=1&amp;md5=d1a812171dbb3c76d879edeca2f7acd3\">https:\/\/www.netroadshow.com\/events\/login?show=ecd4fc1e&amp;confId=76382<\/a><\/p>\n<p>\nAfter registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, March 20, 2025 at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 694296.<\/p>\n<p>\nTo join the webcast, please visit \u201cEvents\u201d on investor relations page of the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.xerispharma.com&amp;esheet=54213235&amp;newsitemid=20250227136020&amp;lan=en-US&amp;anchor=www.xerispharma.com&amp;index=2&amp;md5=63c6653d1fff0f9cf3ac26fd1462cc58\">www.xerispharma.com<\/a> or use this link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FwjIVCR6X0OsrY6zgIESQS17Eek%3Fdomain%3Dgoogle.com&amp;esheet=54213235&amp;newsitemid=20250227136020&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F959090782&amp;index=3&amp;md5=afb5a81b0733a320d0b76dd292a132d4\">https:\/\/events.q4inc.com\/attendee\/959090782<\/a><\/p>\n<p><b>Xeris Biopharma Holdings, Inc.<\/b><\/p>\n<p>\nXeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev\u00ae, for the treatment of endogenous Cushing\u2019s syndrome; Gvoke\u00ae, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis\u00ae, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris\u2019 technology platforms, XeriSol\u00ae and XeriJect\u00ae, for its partners.<\/p>\n<p>\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.xerispharma.com%2F&amp;esheet=54213235&amp;newsitemid=20250227136020&amp;lan=en-US&amp;anchor=www.xerispharma.com&amp;index=4&amp;md5=6307b133ccd7aa5ebf9f993731b725ae\">www.xerispharma.com<\/a>, or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fxerispharma%3Flang%3Den&amp;esheet=54213235&amp;newsitemid=20250227136020&amp;lan=en-US&amp;anchor=X&amp;index=5&amp;md5=f5d1931489172fe3c113e9c55d31bf31\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fxeris-pharmaceuticals%2F&amp;esheet=54213235&amp;newsitemid=20250227136020&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=0fc06c1084d2577d3a7e3bd4ac223f64\">LinkedIn<\/a> or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fxerispharma%2F%3Futm_source%3Dig_profile_share%26igshid%3D5fgt5rqivy22&amp;esheet=54213235&amp;newsitemid=20250227136020&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=51142f07952ab9db1af848c03f768afb\">Instagram<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250227136020\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250227136020\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact<br \/>\n<\/b><br \/>Allison Wey<br \/>\n<br \/>Senior Vice President, Investor Relations and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:awey@xerispharma.com\">awey@xerispharma.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Medical Devices Health Other Health General Health Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250227136020\/en\/2391024\/3\/xeris_BIOPHARMA_TM_L_CMYK_002.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 Conference call and webcast at 8:30am ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results. To pre-register for the call, please go to the following link: https:\/\/www.netroadshow.com\/events\/login?show=ecd4fc1e&amp;confId=76382 After registering, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-818981","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 Conference call and webcast at 8:30am ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results. To pre-register for the call, please go to the following link: https:\/\/www.netroadshow.com\/events\/login?show=ecd4fc1e&amp;confId=76382 After registering, &hellip; Continue reading &quot;Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T12:09:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025\",\"datePublished\":\"2025-02-27T12:09:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"},\"wordCount\":394,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\",\"name\":\"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-27T12:09:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","og_locale":"en_US","og_type":"article","og_title":"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","og_description":"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 Conference call and webcast at 8:30am ET CHICAGO&#8211;(BUSINESS WIRE)&#8211; Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients\u2019 lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial guidance before the open of the U.S. financial markets on Thursday, March 6, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company\u2019s financial and operational results. To pre-register for the call, please go to the following link: https:\/\/www.netroadshow.com\/events\/login?show=ecd4fc1e&amp;confId=76382 After registering, &hellip; Continue reading \"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T12:09:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025","datePublished":"2025-02-27T12:09:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"},"wordCount":394,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/","name":"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-27T12:09:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250227136020r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xeris-biopharma-to-report-fourth-quarter-and-full-year-2024-financial-results-on-march-6-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/818981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=818981"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/818981\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=818981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=818981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=818981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}